Drug Trial Radar · NCT06706713
Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Nov 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Apr 15, 2022
Primary completion
Dec 31, 2025
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- BeBetter Med IncIndustry
- Sponsor type
- Industry
- First posted
- Nov 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, multicenter Phase II trial, planning to enroll 200 subjects, using BEBT-109 capsules as monotherapy, aimed at evaluating the efficacy and safety of BEBT-109 capsules in subjects with Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations in locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC).
Conditions
- Non-Small Cell Lung Cancer
- EGFR Exon 20 Insertion Mutation
Interventions
BEBT-109 CapsuleDrug
Take orally before breakfast and dinner each day, with a minimum interval of 9 hours between doses, 120mg each time, twice a day,and 28 days as a treatment cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: Every 8 weeks,assessed up to 24 months.
- PFSTime frame: Every 8 weeks,assessed up to 24 months.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.